اخبار و اعلانات

 آمار

تعداد نشریات287
تعداد نشریات سازمان85
تعداد شماره‌ها3,159
تعداد مقالات35,108
تعداد مشاهده مقاله50,527,984
تعداد دریافت فایل اصل مقاله90,477,181
Nidhal Ghazy, D, Rahmah Abu- Raghif, A. (1400). Effects of Apremilast on Induced Hypertrophic Scar of Rabbits. سامانه مدیریت نشریات علمی, 76(6), 1803-1813. doi: 10.22092/ari.2021.356195.1800
D Nidhal Ghazy; A Rahmah Abu- Raghif. "Effects of Apremilast on Induced Hypertrophic Scar of Rabbits". سامانه مدیریت نشریات علمی, 76, 6, 1400, 1803-1813. doi: 10.22092/ari.2021.356195.1800
Nidhal Ghazy, D, Rahmah Abu- Raghif, A. (1400). 'Effects of Apremilast on Induced Hypertrophic Scar of Rabbits', سامانه مدیریت نشریات علمی, 76(6), pp. 1803-1813. doi: 10.22092/ari.2021.356195.1800
Nidhal Ghazy, D, Rahmah Abu- Raghif, A. Effects of Apremilast on Induced Hypertrophic Scar of Rabbits. سامانه مدیریت نشریات علمی, 1400; 76(6): 1803-1813. doi: 10.22092/ari.2021.356195.1800

Effects of Apremilast on Induced Hypertrophic Scar of Rabbits

Archives of Razi Institute
مقاله 26، دوره 76، شماره 6، بهمن و اسفند 2021، صفحه 1803-1813    اصل مقاله (1.02 M)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.356195.1800
نویسندگان
D Nidhal Ghazy* ؛ A Rahmah Abu- Raghif
College of Medicine, Al-Nahrain University, Iraq
چکیده
The present study aimed to assess the effect of Apremilast on experimentally induced hypertrophic scars in rabbits. A total of 40 healthy male New Zealand White rabbits between 6 and 12 months of age were assigned to four groups (n=10). Group I consists of apparently healthy control rabbits, in group II, the rabbits with an induced hypertrophic scar received no treatment, except for base gel. In group III, the rabbits with induced hypertrophic scar were treated with triamcinolone acetonide (TAC) 0.1% as standard medication. In group IV, rabbits with induced hypertrophic scars were treated with Apremilast 5%. On the first day, four surgical incisions were made using an 8-mm biopsy punch on the ventral surface of the rabbit ear down to cartilage. The TAC and Apremilast were topically administered to the developed scars on day 31. The results included an examination of skin histopathology, the level of transforming growth factor beta-1 (TGF-β1), and collagen III in skin tissue. In the treatments, the inflammatory score, scar index, as well as immunological scores of TGFβ1 and collagen III, significantly decreased, compared to the hypertrophic induced scar group (P≤ 0.001). Moreover, there was a significant reduction in fibroblast count, compared to the group of induced hypertrophic scars (P<0.05). Apremilast was efficacious in the treatment of hypertrophic scars due to its ability to reduce inflammations and fibroblast counts and scar index. Nonetheless, the reduction of immunological scores was almost comparable to that of topical TAC.
کلیدواژه‌ها
Hypertrophic scar؛ Apremilast؛ SEI؛ TGF-β1
سایر فایل های مرتبط با مقاله
مراجع
  1. Reinke J, Sorg H. Wound repair and regeneration. Eur Surg Res. 2012;49(1):35-43.
  2. George Broughton I, Janis JE, Attinger CE. The basic science of wound healing. Plast Reconstr Surg. 2006;117(7S):12S-34S.
  3. Limandjaja GC, Niessen FB, Scheper RJ, Gibbs S. Hypertrophic scars and keloids: Overview of the evidence and practical guide for differentiating between these abnormal scars. Exp Dermatol. 2021;30(1):146-61.
  4. Ferguson MW, O'Kane S. Scar–free healing: from embryonic mechanisms to adult therapeutic intervention. Philos. Trans R Soc Lond Biol Sci. 2004;359(1445):839-50.
  5. Deng H, Li‐Tsang CW, Li J. Measuring vascularity of hypertrophic scars by dermoscopy: Construct validity and predictive ability of scar thickness change. Skin Res and Technol. 2020;26(3):369-75.
  6. Grabowski G, Pacana MJ, Chen E. Keloid and hypertrophic scar formation, prevention, and management: standard review of abnormal scarring in orthopaedic surgery. J Am Acad Orthop Surg. 2020;28(10):408-14.
  7. Honardoust D, Kwan P, Momtazi M, Ding J, Tredget EE. Novel methods for the investigation of human hypertrophic scarring and other dermal fibrosis. Wound Regeneration and Repair: Springer; 2013. p. 203-31.
  8. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. J Mol Med. 2011;17(1):113-25.
  9. Wang R, Ghahary A, Shen Q, Scott PG, Roy K, Tredget EE. Hypertrophic scar tissues and fibroblasts produce more transforming growth factor‐β1 mRNA and protein than normal skin and cells. Wound Repair Regen. 2000;8(2):128-37.
  10. Pincelli C, Schafer PH, French LE, Augustin M, Krueger JG. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis. J Drugs Dermatol. 2018;17(8):835-40.
  1. Yazdanian N, Mozafarpoor S, Goodarzi A. Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review. Dermatol Ther. 2021;34(1):14669.
  2. Bagel J, Nelson E. Apremilast.  Advances in Psoriasis: Springer. 2021. p. 141-4.
  3. Varada S, Tintle SJ, Gottlieb AB. Apremilast for the treatment of psoriatic arthritis. Expert Rev Clin Pharmacol. 2014;7(3):239-50.
  4. Fala L. Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits. 2015;8:105.
  5. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Deliv. 2006;13(3):175-87.
  6. Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
  7. Caliskan E, Gamsizkan M, Acikgoz G, Durmus M, Toklu S, Dogrul A, et al. Intralesional treatments for hypertrophic scars: comparison among corticosteroid, 5-fluorouracil and botulinum toxin in rabbit ear hypertrophic scar model. Eur Rev Med Pharmacol Sci. 2016;20(8):1603-8.
  8. Dadashpour Davachi N, Bartlewski PM, Masoudi R, Ahmadi B, Didarkhah M. Induction of ovulation after artificial insemination in rabbits: Intramuscular injection of gonadotropin-releasing hormone (GnRH) agonist vs. intravenous administration of mated doe serum . Iran J Vet Med. 2021.
  9. Singh M, Nagori B, Shaw N, Tiwari M, Jhanwar B. Formulation development & evaluation of topical gel formulations using different gelling agents and its comparison with marketed gel formulation. Int J Pharm Erud. 2013;3(3):1-10.
  10. Pullar CE, Le Provost GS, O'leary AP, Evans SE, Baier BS, Isseroff RR. β2AR antagonists and β2AR gene deletion both promote skin wound repair processes. J Investig Dermatol. 2012;132(8):2076-84.
  11. Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast Reconstr Surg. 2002;110(1):177-83.
  12. Souil E, Capon A, Mordon S, Dinh‐Xuan A, Polla B, Bachelet M. Treatment with 815‐nm diode laser induces long‐lasting expression of 72‐kDa heat shock protein in normal rat skin. Br J Dermatol. 2001;144(2):260-6.
  13. Prignano F, Campolmi P, Bonan P, Ricceri F, Cannarozzo G, Troiano M, et al. Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther. 2009;22:S8-S15.
  14. Daniel WW, Cross CL. Biostatistics: a foundation for analysis in the health sciences: Wiley. 2018.
  15. Rabello FB, Souza CD, Farina JA. Update on hypertrophic scar treatment. Clinics. 2014;69:565-73.
  16. Mullard A. New drugs cost US $2.6 billion to develop. Nat Rev Drug Discov. 2014;13(12):877.
  17. Pan Y, Chen Z, Qi F, Liu J. Identification of drug compounds for keloids and hypertrophic scars: drug discovery based on text mining and DeepPurpose. Ann Transl Med. 2021;9(4).
  18. Zhang Q, Liu L-N, Yong Q, Deng J-C, Cao W-G. Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model. Stem Cell Res Ther. 2015;6(1):1-11.
  19. Shirakami E, Yamakawa S, Hayashida K. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns trauma. 2020;8.
  20. Supp DM. Animal models for studies of keloid scarring. Adv Wound Care. 2019;8(2):77-89.
  21. Moosavinasab S, Patterson J, Strouse R, Rastegar-Mojarad M, Regan K, Payne PR, et al. ‘RE: fine drugs’: an interactive dashboard to access drug repurposing opportunities. Database. 2016;2016.
  22. Nabai L, Pourghadiri A, Ghahary A. Hypertrophic scarring: current knowledge of predisposing factors, cellular and molecular mechanisms. J Burn Care Res. 2020;41(1):48-56.
  23. Wang J, Dodd C, Shankowsky HA, Scott PG, Tredget EE. Deep dermal fibroblasts contribute to hypertrophic scarring. Lab Invest. 2008;88(12):1278-90.
  24. Pessoa ES, Melhado RM, Theodoro LH, Garcia histologic assessment of the influence of low-intensity laser therapy on wound healing in steroid-treated animals. Photomed Laser Surg. 2004;22(3):199-204.
  25. Carroll LA, Hanasono MM, Mikulec AA, Kita M, Koch RJ. Triamcinolone stimulates bFGF production and inhibits TGF‐β1 production by human dermal fibroblasts. Dermatol Surg. 2002;28(8):704-9.
  26. Nischwitz SP, Rauch K, Luze H, Hofmann E, Draschl A, Kotzbeck P, et al. Evidence‐based therapy in hypertrophic scars: An update of a systematic review. Wound Repair Regen. 2020;28(5):656-65.
  27. Uzun H, Bitik O, Hekimoglu R, Atilla P, Kaykçoglu AU. Angiotensin-converting enzyme inhibitor enalapril reduces formation of hypertrophic scars in a rabbit ear wounding model. Plast Reconstr Surg. 2013;132(3):361-71.
  28. Sarango-Granda P, Silva-Abreu M, Calpena AC, Halbaut L, Fábrega M-J, Rodríguez-Lagunas MJ, et al. Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation. Pharmaceuticals. 2020;13(12):484.
  29. Schafer P, Parton A, Gandhi A, Capone L, Adams M, Wu L, et al. Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-55.
  30. Cosmi L, Maggi L, Santarlasci V, Liotta F, Annunziato F. T helper cells plasticity in inflammation. Cytometry A. 2014;85(1):36-42.
  31. Schafer P, Parton A, Capone L, Cedzik D, Brady H, Evans J, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016-29.
  32. Huff SB, Gottwald LD. Repigmentation of tenacious vitiligo on apremilast. Case Rep Dermatol Med. 2017;2017.
  33. Thangapazham RL, Sharma A, Maheshwari RK. Beneficial role of curcumin in skin diseases. Adv Exp Med Biol. 2007:343-57.
آمار
تعداد مشاهده مقاله: 15,288
تعداد دریافت فایل اصل مقاله: 66,448


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب